These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10524594)

  • 1. Immune mediated 'HAART' attack during treatment for tuberculosis. Highly active antiretroviral therapy.
    Kunimoto DY; Chui L; Nobert E; Houston S
    Int J Tuberc Lung Dis; 1999 Oct; 3(10):944-7. PubMed ID: 10524594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune reconstitution syndrome following initiation of antiretroviral therapy in a patient with HIV infection and multidrug-resistant tuberculosis.
    Swaminathan S; Padmapriyadarsini C; Narendran G; Thomas BE; Anand S; Rajyalakshmi A
    Indian J Chest Dis Allied Sci; 2005; 47(4):299-304. PubMed ID: 16255403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercalcaemia complicating immune reconstitution in an HIV-infected patient with disseminated tuberculosis.
    Ferrand RA; Elgalib A; Newsholme W; Childerhouse A; Edwards SG; Miller RF
    Int J STD AIDS; 2006 May; 17(5):349-50. PubMed ID: 16643687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART.
    Zanoni BC; Phungula T; Zanoni HM; France H; Feeney ME
    AIDS; 2011 Jan; 25(1):49-55. PubMed ID: 20935555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
    Breen RA; Miller RF; Gorsuch T; Smith CJ; Ainsworth J; Ballinger J; Swaden L; Cropley I; Johnson MA; Lipman MC
    J Infect Dis; 2006 May; 193(10):1437-40. PubMed ID: 16619192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A diagnostic dilemma in a patient receiving antiretroviral and antituberculosis therapy.
    Vallabhaneni S; Kumarasamy N; Wing EJ; Flanigan TP
    AIDS Read; 2005 Feb; 15(2):72-5. PubMed ID: 15712396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection.
    Breen RA; Smith CJ; Bettinson H; Dart S; Bannister B; Johnson MA; Lipman MC
    Thorax; 2004 Aug; 59(8):704-7. PubMed ID: 15282393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?
    Miller RF; Shahmanesh M; Talbot MD; Wiselka MJ; Shaw PJ; Bacon C; Robertson CM
    Sex Transm Infect; 2006 Apr; 82(2):111-6. PubMed ID: 16581733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful administration of aggressive chemotherapy concomitant to tuberculostatic and highly active antiretroviral therapy in a patient with AIDS-related Burkitt's lymphoma.
    Lehmann C; Wyen C; Hoffmann C; Fätkenheuer G
    HIV Med; 2005 Jan; 6(1):51-3. PubMed ID: 15670254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence of Mycobacterium avium infection in patients receiving highly active antiretroviral therapy and antimycobacterial agents.
    Cinti SK; Kaul DR; Sax PE; Crane LR; Kazanjian PH
    Clin Infect Dis; 2000 Mar; 30(3):511-4. PubMed ID: 10722436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple tuberculous brain abscesses in an HIV-infected patient successfully treated with HAART and antituberculous treatment.
    Bottieau E; Noë A; Florence E; Colebunders R
    Infection; 2003 Mar; 31(2):118-20. PubMed ID: 12682819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing delay in initiating antiretroviral therapy among HIV infected patients coinfected with tuberculosis.
    Chilton D; Edwards SG; Pellegrino P; Miller RF
    Thorax; 2008 Oct; 63(10):935-6. PubMed ID: 18820121
    [No Abstract]   [Full Text] [Related]  

  • 14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First UK report of successful treatment of Mycobacterium simiae and immune reconstitution inflammatory syndrome in an HIV-seropositive patient.
    Phillips DR; Krishnan H; Watson J
    Sex Transm Infect; 2008 Aug; 84(4):271-2. PubMed ID: 18647877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV and tuberculosis--a "cursed duo" in the HAART era.
    Londhey VA
    J Assoc Physicians India; 2009 Oct; 57():681-2. PubMed ID: 20329423
    [No Abstract]   [Full Text] [Related]  

  • 18. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycobacterial diseases and HIV.
    Pozniak A
    J HIV Ther; 2002 Feb; 7(1):13-6. PubMed ID: 11956499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunistic infections shortly after beginning highly active antiretroviral therapy.
    Rodríguez-Rosado R; Soriano V; Dona C; González-Lahoz J
    Antivir Ther; 1998; 3(4):229-31. PubMed ID: 10682143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.